Pull to refresh
Logo
Akeso Inc.

Akeso Inc.

Biopharmaceutical company (Hong Kong-listed)

Appears in 3 stories · Last updated Nov 17, 2026

Stories

FDA rejects ivonescimab over missing survival benefit

Rule Changes

Inventor of ivonescimab; Hong Kong-listed shares fell after US rejection

Summit Therapeutics' shares fell 15% on Nov. 16. The drop followed the Food and Drug Administration's rejection of ivonescimab, a lung cancer drug that targets two proteins called PD-1 and VEGF and had drawn attention as a potential challenge to Merck's Keytruda. The agency issued a complete response letter, meaning the application cannot be approved in its current form.

Updated 48 minutes ago

Ivonescimab regimen tops durvalumab in biliary tract cancer trial

New Capabilities

Sponsor of HARMONi-GI1; developed ivonescimab

Patients with advanced biliary tract cancer lived a median of 14.9 months on ivonescimab plus chemotherapy, versus 12.1 months on durvalumab (Imfinzi) plus chemo. That is a 25% lower risk of death in the Phase III HARMONi-GI1 trial, which Akeso presented at the ESMO 2026 Presidential Symposium in Madrid on October 25.

Updated Oct 27

AstraZeneca invests $2 billion in Summit Therapeutics for ADC combination strategy

Money Moves

Engineered ivonescimab; retains rights in China

AstraZeneca closed its $2 billion Summit Therapeutics investment on October 5: a straight equity purchase with no royalties or milestones attached, according to Biotech Morning. The cash funds trials pairing Summit's ivonescimab, a bispecific antibody that blocks PD-1 and VEGF, with AstraZeneca's antibody-drug conjugates.

Updated Oct 21